子宫内膜异位症非激素类药物的研究进展

doi:10.12280/gjfckx.20200970

摘要/Abstract

摘要：

随着对子宫内膜异位症（endometriosis,EMs）发病机制研究逐渐深入,认识到EMs不只是激素依赖性疾病,炎症、免疫系统紊乱、氧化应激失调等也参与子宫内膜碎片在“异地”的黏附、侵袭和生长,这些微环境的异常为EMs的非激素类药物治疗提供了新的研究方向。介绍肿瘤坏死因子α（TNF-α）抑制剂、3-羟基-3甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂、大环内酯类药物、瘦素及瘦素受体拮抗剂、植物类药物等非激素类药物应用于EMs中的研究进展,帮助临床工作者了解非激素类药物治疗前景。

关键词: 子宫内膜异位症, 羟甲基戊二酰基CoA还原酶抑制剂, 大环内酯类, 姜黄素, 非激素类药物, 肿瘤坏死因子α抑制剂, 抗瘦素信号

Abstract:

With the development of the research on the pathogenesis of endometriosis(EMs), EMs is no longer a hormone-dependent disease, inflammation, immune dysfunction and oxidative stress disorder are also involved in the adhesion, invasion and growth of endometriosis fragments in "different places". These abnormalities in the endometrial microenvironment provide new research directions for the treatment of EMs with non-hormonal drugs. This review focuses on the research progress of non-hormonal drugs such as TNF-α inhibitors, HMG-CoA reductase inhibitors, macrolides, leptin and leptin receptor antagonist and plants, for clinical workers to better understand the therapeutic prospect of non-hormonal drugs.

Key words: Endometriosis, Hydroxymethylglutaryl-CoA reductase inhibitors, Macrolides, Curcumin, Non-hormones drug, Tumor necrosis factor-alpha inhibitors, Anti-leptin signaling

王英巧, 李咏, 孔成才. 子宫内膜异位症非激素类药物的研究进展[J]. 国际妇产科学杂志, 2021, 48(3): 286-289.

WANG Ying-qiao, LI Yong, KONG Cheng-cai. Advances in Non-Hormonal Drugs of Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2021, 48(3): 286-289.

参考文献 30

[1]	Wang Y, Nicholes K, Shih IM. The Origin and Pathogenesis of Endometriosis[J]. Annu Rev Pathol, 2020,15:71-95. doi: 10.1146/annurev-pathmechdis-012419-032654. doi: 10.1146/annurev-pathmechdis-012419-032654 pmid: 31479615
[2]	Samimi M, Pourhanifeh MH, Mehdizadehkashi A, et al. The role of inflammation, oxidative stress, angiogenesis, and apoptosis in the pathophysiology of endometriosis: Basic science and new insights based on gene expression[J]. J Cell Physiol, 2019,234(11):19384-19392. doi: 10.1002/jcp.28666. doi: 10.1002/jcp.28666
[3]	Lin YH, Chen YH, Chang HY, et al. Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies[J]. Int J Mol Sci, 2018,19(8):2385. doi: 10.3390/ijms19082385. doi: 10.3390/ijms19082385
[4]	Scutiero G, Iannone P, Bernardi G, et al. Oxidative Stress and Endometriosis: A Systematic Review of the Literature[J]. Oxid Med Cell Longev, 2017,2017:7265238. doi: 10.1155/2017/7265238. doi: 10.1155/2017/7265238 pmid: 29057034
[5]	彭丽娜, 安春晓, 张广美. 子宫内膜异位症的药物治疗[J]. 国际妇产科学杂志, 2020,47(6):694-698,711. doi: 10.3969/j.issn.1674-1870.2020.06.020. doi: 10.3969/j.issn.1674-1870.2020.06.020
[6]	Wang XM, Ma ZY, Song N. Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis[J]. Eur Rev Med Pharmacol Sci, 2018,22(9):2513-2518. doi: 10.26355/eurrev_201805_14899. doi: 14899 pmid: 29771400
[7]	Kolanska K, Alijotas-Reig J, Cohen J, et al. Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy[J]. Am J Reprod Immunol, 2020,e13384. doi: 10.1111/aji.13384. doi: 10.1111/aji.13384
[8]	Lang Q, Yidong X, Xueguang Z, et al. ETA-mediated anti-TNF-α therapy ameliorates the phenotype of PCOS model induced by letrozole[J]. PLoS One, 2019,14(6):e0217495. doi: 10.1371/journal. pone.0217495. doi: 10.1371/journal. pone.0217495
[9]	郭晓强. 肿瘤坏死因子抑制剂开发史:转化医学的成功范式[J]. 自然杂志, 2020,42(2):142-150. doi: 10.3969/j.issn.0253-9608.2020. 02.010. doi: 10.3969/j.issn.0253-9608.2020. 02.010
[10]	Geldhof A, Slater J, Clark M, et al. Exposure to Infliximab During Pregnancy: Post-Marketing Experience[J]. Drug Saf, 2020,43(2):147-161. doi: 10.1007/s40264-019-00881-8. doi: 10.1007/s40264-019-00881-8 pmid: 31677004
[11]	Önalan G, Tohma YA, Zeyneloğlu HB. Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma[J]. Gynecol Obstet Invest, 2018,83(4):358-364. doi: 10.1159/000484895. doi: 10.1159/000484895
[12]	王青, 段华, 张颖. 他汀类药物在治疗子宫内膜异位症中的基础研究进展[J]. 实用妇产科杂志, 2020,36(10):745-747.
[13]	Almassinokiani F, Mehdizadeh A, Sariri E, et al. Effects of simvastatin in prevention of pain recurrences after surgery for endometriosis[J]. Med Sci Monit, 2013,19:534-539. doi: 10.12659/MSM.883967. doi: 10.12659/MSM.883967
[14]	Waiyaput W, Pumipichet S, Weerakiet S, et al. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial[J]. BMC Womens Health, 2017,17(1):89. doi: 10.1186/s12905-017-0446-3. doi: 10.1186/s12905-017-0446-3 pmid: 28950844
[15]	Laschke MW, Elitzsch A, Scheuer C, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation[J]. Br J Pharmacol, 2006,149(2):137-144. doi: 10.1038/sj.bjp.0706857. doi: 10.1038/sj.bjp.0706857
[16]	Wang Y, Zhu L, Kuokkanen S, et al. Activation of protein synjournal in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC-ERK1/2-mTOR signaling pathway[J]. Proc Natl Acad Sci U S A, 2015,112(11):E1382-1391. doi: 10.1073/pnas.1418973112. doi: 10.1073/pnas.1418973112
[17]	Umezawa M, Tanaka N, Takeda K, et al. Clarithromycin and telithromycin increases interleukin-10 expression in the rat endometriosis model[J]. Cytokine, 2011,55(3):339-342. doi: 10.1016/j.cyto.2011.05.014. doi: 10.1016/j.cyto.2011.05.014
[18]	Cavkaytar S, Tapisiz OL, Kiykac Altinbas S, et al. Clarithromycin regresses endometriotic implants in rat endometriosis model[J]. J Obstet Gynaecol, 2015,35(8):844-847. doi: 10.3109/01443615.2015. 1022140. doi: 10.3109/01443615.2015.1022140 pmid: 26156575
[19]	Alborzi S, Poordast T, Askary E, et al. Effects of clarithromycin on inflammatory markers and clinical manifestations in postsurgical follow-up of patients with endometriosis: a double-blinded randomized placebo-controlled clinical trial[J]. Arch Gynecol Obstet, 2019,299(5):1305-1312. doi: 10.1007/s00404-019-05057-4. doi: 10.1007/s00404-019-05057-4
[20]	Imterat M, Agarwal A, Esteves SC, et al. Impact of Body Mass Index on female fertility and ART outcomes[J]. Panminerva Med, 2019,61(1):58-67. doi: 10.23736/S0031-0808.18.03490-0. doi: 10.23736/S0031-0808.18.03490-0 pmid: 29962181
[21]	Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, et al. Role of Leptin in Inflammation and Vice Versa[J]. Int J Mol Sci, 2020,21(16):5887. doi: 10.3390/ijms21165887. doi: 10.3390/ijms21165887
[22]	Ahn JH, Choi YS, Choi JH. Leptin promotes human endometriotic cell migration and invasion by up-regulating MMP-2 through the JAK2/STAT3 signaling pathway[J]. Mol Hum Reprod, 2015,21(10):792-802. doi: 10.1093/molehr/gav039. doi: 10.1093/molehr/gav039
[23]	Tian Z, Wang Y, Zhao Y, et al. Serum and peritoneal fluid leptin levels in endometriosis: a systematic review and meta-analysis[J]. Gynecol Endocrinol, 2020 Dec 23: 1-5. doi: 10.1080/09513590. 2020.1862789. Epub ahead of print. doi: 10.1080/09513590. 2020.1862789. Epub ahead of print
[24]	Zabeau L, Peelman F, Tavernier J. Leptin: From structural insights to the design of antagonists[J]. Life Sci, 2015,140:49-56. doi: 10.1016/j.lfs.2015.04.015. doi: 10.1016/j.lfs.2015.04.015
[25]	Zabeau L, Wauman J, Dam J, et al. A novel leptin receptor antagonist uncouples leptin′s metabolic and immune functions[J]. Cell Mol Life Sci, 2019,76(6):1201-1214. doi: 10.1007/s00018-019-03004-9. doi: 10.1007/s00018-019-03004-9
[26]	Vallée A, Lecarpentier Y. Curcumin and Endometriosis[J]. Int J Mol Sci, 2020,21(7):2440. doi: 10.3390/ijms21072440. doi: 10.3390/ijms21072440
[27]	Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability[J]. Biol Pharm Bull, 2011,34(5):660-665. doi: 10.1248/bpb.34.660. doi: 10.1248/bpb.34.660
[28]	Medical University of Vienna. Flexofytol ® for the Treatment of Endometriosis-Associated Pain (ENDOFLEX) [EB/OL]. [2019-11-04]. https://clinicaltrials.gov/show/NCT04150406.
[29]	Lu D, Song H, Li Y, et al. Pentoxifylline for endometriosis[J]. Cochrane Database Syst Rev, 2012, 1:CD007677. doi: 10.1002/14651858.CD007677.pub3. doi: 10.1002/14651858.CD007677.pub3
[30]	Meresman GF, Götte M, Laschke MW. Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies[J]. Hum Reprod Update, 2021,27(2):367-392. doi: 10.1093/humupd/dmaa039. doi: 10.1093/humupd/dmaa039